News and Trends 5 Mar 2018 Swiss Company Hits Another Slump with a Failed Multiple Sclerosis Trial Just months after the EMA rejected its therapy for Duchenne muscular dystrophy, Swiss company Santhera reports negative data for its multiple sclerosis drug. Santhera Pharmaceuticals has reported this morning that a first clinical trial in patients with primary progressive multiple sclerosis (PPMS) failed to prove the company’s drug to have any effect on the progression of […] March 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2018 Doudna and Charpentier Get Second CRISPR Patent in Europe Just a month after the European Patent Office revoked a CRISPR patent from the competitors of Doudna and Charpentier, they have been granted a second patent that covers a new form of the popular gene editing tool. The European Patent Office has granted CRISPR co-inventor Emmanuelle Charpentier, together with the University of California and the University […] March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2018 How is Actelion Spin-Off Idorsia Doing One Year Later? Actelion’s spin-off Idorsia was blessed with a large pipeline and a healthy bank balance. How has the biotech’s first year of business gone? Just over a year ago, Actelion, the largest biotech in Europe at the time, was snapped up by Johnson & Johnson for a massive €27.9Bn. “This deal is unique: J&J gets its […] March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 24 Feb 2018 The First and Only Museum of Microbes Captivates Amsterdam Micropia, a museum of microbes located in the heart of Amsterdam, uses art to address the big knowledge gap between science and the general public. Microbiology originated just a few kilometers from Amsterdam when Antoni van Leeuwenhoek built one of the first microscopes and discovered that everyday objects, as well as himself, were teeming with minuscule forms of life. More […] February 24, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Infographics 21 Feb 2018 Infographic: The Landscape of Plant Biotechnology in Europe From electricity to medicine, the field of plant biotechnology is full of cool applications. We’ve gathered some of the coolest plant biotechs in Europe in this infographic. When you hear about plant biotechnology, I bet you think of the infamous GMO crops of the likes of Monsanto. But the field goes well beyond that, with an […] February 21, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Feb 2018 Microsoft Joins Shire to Diagnose Rare Diseases Much Faster Microsoft has partnered with Shire and EURORDIS to accelerate the diagnosis of rare disease, a process that often takes years and takes a big toll on the health of millions. There are over 6,000 different rare diseases, most of them beginning in childhood. However, diagnosing them takes an average of 5 years, delaying the start […] February 20, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 19 Feb 2018 Taking CAR-T Cells Beyond Cancer: A New Therapy for Autoimmune Disease CAR-T cells are all the rage as the latest treatment for cancer. But what if we could apply this same technology to treat autoimmune disease? Curious to learn whether this new technology could revolutionize yet another field of medicine, I talked to Stephane Boissel, CEO of TxCell, to discuss the future of the field and his […] February 19, 2018 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2018 French Biotech Gets a CRISPR Patent for CAR-T Research Update (16/02/2018): On top of the European patent it got last July, Cellectis now also has two US patents to use CRISPR technology to make CAR-T cells. Cellectis has said it will offer licenses to companies that want to use CRISPR gene editing in T cells. Not just for inserting CAR antigens, but also other editions […] February 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2018 This Mobile Diabetes Management System Can Reduce Hypoglycemia by 39% The wireless system for diabetes management developed by Cellnovo can significantly reduce life-threatening events of hypoglycemia in patients with type 1 diabetes. A clinical study that followed type 1 diabetes patients for a year has concluded that a new mobile system for diabetes management could reduce events of hypoglycemia by 29% in adults — from […] February 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2018 Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval Update (13/02/2018): The European Commission has given Novo Nordisk a market authorization for Ozempic (semaglutide), bringing the competition for Eli Lilly’s Trulicity over to Europe. Eli Lilly executives have said that they are not worried by Novo’s competition, and keep confident on the performance of Trulicity, which now tops 40% of the market share of diabetes drugs belonging […] February 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2018 Superbugs: Fighting Antibiotic Resistance at the Science Museum An exhibition at the Science Museum London features some of the deadliest superbugs on Earth and the stories of the people fighting against the threat of antibiotic resistance. It is estimated that, by 2050, 10 million people will die every year due to infections with antibiotic-resistant bacteria. Meaning that the numbers will be higher than […] February 10, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Feb 2018 GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment ViiV Healthcare has just started a clinical trial to test if its two-drug regimen for HIV can work as well as current three-drug HIV treatment. Most antiretroviral treatments used to keep HIV at bay employ a combination of three different drugs, exposing patients to the long-term toxicity of three different compounds at once. London-based ViiV […] February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email